Nurix Therapeutics analyst upgrades to Buy rating
NRIX
Statements (5)
- Bullish
Nurix Therapeutics, Inc. is likely to see its stock price rise following the analyst price target increase to $33 due to the reported Roche partnership value.
- Bullish
Baird increased its price target on Nurix Therapeutics, Inc. (NRIX) to $33 from $26
- Bullish
Nurix Therapeutics, Inc. (NRIX) shares are likely to rise following Truist analyst Gregory Renza's rating upgrade to Buy and price target increase to $32.
- Bullish
Truist analyst Gregory Renza maintained Buy rating on Nurix Therapeutics, Inc. shares
- Bullish
Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. price target to $32 from $30